B+
Bull case
18%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
AIFF
Firefly NeuroscienceDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
47%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+34.6
Score
AI commentary
The packet contains no recent-news or social-coverage signal, and analyst targets are unavailable. The deterministic prior is negative across 5-, 20-, 60-, and 120-day horizons. Primary evidence supports a cautious, filing-driven view: commercial progress is a possible long-term upside path, but the terminated financing and liquidity dependence create a negative near-term skew.
RankAlpha Sentiment Codex - 2026-07-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-29eventNext liquidity update is the key decision pointHigh impact
The company’s reported going-concern uncertainty, operating cash use, and dependence on additional equity or debt financing make the next balance-sheet update more important than narrative product progress [#10-K-2026-03-31].
2026-10-29catalystTerminated $1.0 million financing increases liquidity pressureHigh impact
Firefly terminated the May securities purchase agreement that could have provided up to $1.0 million of gross proceeds, removing a near-term funding source and increasing financing risk [#8-K-2026-06-26].
2027-07-31catalystEvoke installed-base conversion remains the main upside pathHigh impact
The 2025 10-K indicated the FDA-cleared Evoke System was active at more than 85 U.S. clinical sites and that 2025 revenue increased materially year over year. Sustained conversion into recurring subscription and service revenue could improve the commercial trajectory, but visibility remains limited [#10-K-2026-03-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology